Abstract

Malaria, caused by the Plasmodium parasite, remains a serious global public health concern. A vaccine could have a substantial impact on eliminating this disease, alongside other preventative measures. We recently described the development of three novel, viral vectored vaccines expressing either of the antigens PfUIS3, PfLSA1 and PfLSAP2. Each vaccination regimen provided high levels of protection against chimeric parasite challenge in a mouse model, largely dependent on CD8+ T cells. In this study we aimed to further characterize the induced cellular immune response to these vaccines. We utilized both the IFNγ enzyme-linked immunosorbent spot assay and intracellular cytokine staining to achieve this aim. We identified immunodominant peptide responses for CD4+ and CD8+ T cells for each of the antigens in BALB/c, C57BL/6 and HLA-A2 transgenic mice, creating a useful tool for researchers for subsequent study of these antigens. We also compared these immunodominant peptides with those generated from epitope prediction software, and found that only a small proportion of the large number of epitopes predicted by the software were identifiable experimentally. Furthermore, we characterized the polyfunctionality of the induced CD8+ T cell responses. These findings contribute to our understanding of the immunological mechanisms underlying these protective vaccines, and provide a useful basis for the assessment of these and related vaccines as clinical constructs.

Highlights

  • Malaria, caused by the Plasmodium parasite, remains an infectious disease of global concern and there is widespread agreement that a vaccine is needed to eliminate this pathogen [1]

  • We demonstrated that both PfLSA1 and PfLSAP2, when delivered using the viral vectors chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) with an eight-week interval, could protect 70–87.5% of both inbred and outbred mice against chimeric P. berghei parasites expressing the cognate P. falciparum antigen

  • Immunodominant peptides were first identified by IFNγ enzyme-linked immunosorbent spot (ELISpot) using splenocytes from mice vaccinated with the ChAd63-MVA regimen, as described in the Materials and Methods

Read more

Summary

Introduction

Malaria, caused by the Plasmodium parasite, remains an infectious disease of global concern and there is widespread agreement that a vaccine is needed to eliminate this pathogen [1]. Whilst recent results using the pre-erythrocytic sub-unit vaccine RTS,S/AS01 are encouraging [2], substantial increases in efficacy and durability are still required.

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call